Logo
x

Search

Subscribe Now

eisai

Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease

Eisai and Biogen Reports the CHMP’s Positive Opinion of Lecanemab to Treat Early Alzheimer’s Disease

  • November 15, 2024
Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

  • January 18, 2024
Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

  • January 9, 2024
Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

  • December 13, 2023
Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023

Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023

  • October 26, 2023
Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

  • July 5, 2023
Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

    Eisai’s Fycompa (perampanel) Injection Formulation Receives MHLW’s Marketing Authorization for Epilepsy

    • January 18, 2024
    PharmaShots Weekly Snapshots (January 08 – January 12, 2024)

      PharmaShots Weekly Snapshots (January 08 – January 12, 2024)

      • January 12, 2024
      Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

        Eisai and Biogen’s Leqembi (Lecanemab) Receives the NMPA’s Approval for the Treatment of Alzheimer’s Disease

        • January 9, 2024
        ANGLE Signs a Contract with Eisai for Liquid Biopsy Diagnostic Solution

          ANGLE Signs a Contract with Eisai for Liquid Biopsy Diagnostic Solution

          • January 2, 2024
          PharmaShots Weekly Snapshots (December 11 – December 15, 2023)

            PharmaShots Weekly Snapshots (December 11 – December 15, 2023)

            • December 15, 2023
            Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

              Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)

              • December 13, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.